EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, FBIO: Fortress Biotech Inc

31 Oct 25 08:49
LAST:

2.520

CHANGE:
 0.05		OPEN:
2.520		HIGH:
2.520		ASK:
3.140		VOLUME:
130
CHG(%):
1.95		PREV:
2.570		LOW:
2.520		BID:
3.050		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
31 Oct 252.5202.5202.5202.520130
30 Oct 252.5202.5902.4802.570400.3K
29 Oct 252.5602.5602.4802.520380.6K
28 Oct 252.5902.5902.5102.560225.8K
27 Oct 252.5302.6102.4702.570376.6K
24 Oct 252.5402.5902.5002.510366.1K
23 Oct 252.6402.6452.5102.520552.8K
22 Oct 252.7502.7902.5202.540625.4K
21 Oct 252.7302.8702.7102.770386.0K
20 Oct 252.7902.8152.6602.760579.9K

COMPANY PROFILE

Name:Fortress Biotech Inc
About:Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Sector:Healthcare
Industry:Biotechnology
Address:1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
Website:https://www.fortressbiotech.com
CUSIP:21976U109
CIK:0001429260
ISIN:US34960Q3074
FIGI:BBG001J2MFH6

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:2.551.1%
MA10:2.582.5%
MA20:2.717.6%
MA50:3.0420.7%
MA100:2.481.7%
MA200:2.0920.4%
STO9:2.78 
STO14:2.56 
RSI14:32.93 
WPR14:-96.77 
MTM14:-0.21
ROC14:-0.08 
ATR:0.14 
Week High:2.613.6%
Week Low:2.472.0%
Month High:3.9757.5%
Month Low:2.2620.4%
Year High:4.2066.7%
Year Low:1.3389.5%
Volatility:130.96 

RECENT SPLITS

Date Ratio
10 Oct 20231-15